India Glycols has confirmed that its demerger scheme into three distinct entities is now effective as of September 1, 2026. The company filed the certified true copy of the National Company Law Tribunal (NCLT) order with the Registrar of Companies on this date, finalizing the separation of its business verticals.

Demerger structure and effective date

The corporate restructuring results in three separate companies emerging from the current India Glycols entity. The NCLT, Allahabad Bench, sanctioned the Scheme of Arrangement among India Glycols Limited (the Demerged Company), Ennature Bio Pharma Limited (Resulting Company 1), and IGL Spirits Limited (Resulting Company 2).

The effective date of the scheme is September 1, 2026. Consequently, the resulting companies have ceased to be subsidiaries of India Glycols Limited.

Shareholding pattern and listing

Shareholders holding India Glycols shares on the record date of September 2, 2026, will receive shares in the new entities based on a specific ratio. For every one equity share held in India Glycols Limited, shareholders are entitled to:

• One equity share of IGL Spirits Limited.
• One equity share of Ennature Bio Pharma Limited for every three equity shares held in India Glycols Limited.

For example, a shareholder with 300 India Glycols shares will receive 300 IGL Spirits shares and 100 Ennature Bio Pharma shares, totaling 700 shares across the three entities. India Glycols Limited remains listed on both BSE and NSE. The management of IGL Spirits Limited and Ennature Bio Pharma Limited will apply for listing of their shares on the respective bourses.

Strategic benefits

The demerger aims to create three separate companies with clear business focus. This structure enables improved management oversight and efficient allocation of resources towards growth. Each entity can now manage its capital, investments, and resources based on specific business requirements, facilitating more efficient capital utilization.

India Glycols Limited has announced a physical group meeting with analysts and institutional investors scheduled for September 2, 2026. The event will take place in Mumbai starting at 5:00 pm IST.

The company issued the disclosure on August 28, 2026, pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The notice was communicated to the listing managers at both the Bombay Stock Exchange and the National Stock Exchange of India.

Meeting Details

The interaction is structured as a physical group meeting. Participants should note that the schedule is subject to change due to exigencies on the part of the participants, host, or company.

Scope of Discussion

The company explicitly stated that discussions during the interaction will be based solely on publicly available information. No unpublished price-sensitive information (UPSI) is intended to be discussed.

Ankur Jain, Head (Legal) & Company Secretary, signed the disclosure. The notice is also hosted on the company’s official website for public record.